Re-Use of Established Drugs for Anti-Metastatic Indications
Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate s...
Main Authors: | Frank Entschladen, Dane A. Thyssen, David W. Drell |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-01-01
|
Series: | Cells |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4409/5/1/2 |
Similar Items
-
Anti-metastatic Action of Non-steroidal Anti-inflammatory Drugs
by: Wen-Chun Hung
Published: (2008-08-01) -
Zebrafish-Based Screening Models for the Identification of Anti-Metastatic Drugs
by: Joji Nakayama, et al.
Published: (2020-05-01) -
Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
by: Ivy Chung, et al.
Published: (2021-03-01) -
Re-Envisioning Anti-Apicomplexan Parasite Drug Discovery Approaches
by: Gabriel W. Rangel, et al.
Published: (2021-06-01) -
The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials
by: Xi Cheng, et al.
Published: (2021-01-01)